Nautilus Biotechnology, Inc. (NAUT)
|Net Income (ttm)||n/a|
|Trading Day||June 22|
|Day's Range||9.17 - 9.41|
|52-Week Range||8.85 - 11.69|
Nautilus Biotechnology is emerging as Seattle's newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biom...
Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Pro...
SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the c...
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III (“ARYA”) (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COV...
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology appoints Matt Murphy, former 10x Genomics and Pacific Biosciences executive, as General Counsel
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp. III ("AR...
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Co...
SEATTLE & NEW YORK--(BUSINESS WIRE)--Nautilus Biotechnology, Inc. ("Nautilus Biotechnology" or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human pro...
There is no company description available.
|Stock Exchange |
|Ticker Symbol |